On November 4, 2025 Grit Biotherapeutics Co., Ltd. ("Grit Bio"), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, reported that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the upcoming 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, to be held December 6–9, 2025, in Orlando, Florida, USA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled "Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable and Translatable Cell Therapy," was accepted in the CAR-T Cell Therapies: Basic and Translational session. The presentation will be delivered by Professor Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, on Saturday, December 6, 9:30–9:45 AM (local time) at the OCCC – Sunburst Room (W340).
GT801 is an innovative anti-CD19 in vivo CAR-T candidate developed using T-cell-targeted lipid nanoparticles (T-LNPs) encapsulating optimized mRNA. Grit Bio leveraged the proprietary CLAMP (Controllable Ligand Attachment Modification and Purification) technology to achieve site-specific antibody conjugation and precise ligand density control. This approach allows selective T-cell targeting, minimal off-target uptake, and robust, durable CAR expression following systemic administration.
In preclinical studies, GT801 demonstrated:
>95% B-cell clearance in humanized PBMC mouse models at doses as low as 0.01 mg/kg;
>80% CAR expression across tissue-resident T cells with <1% off-target delivery to myeloid and hepatic cells;
>30-fold in vivo expansion of CAR-T cells with minimal cytokine release (IL-6, TNF-α), supporting the safety and feasibility of repeat dosing.
Preliminary clinical data further validate efficient CAR expression, deep B-cell depletion, and repeat-dose tolerability, highlighting GT801’s strong potential as a scalable, off-the-shelf immunotherapy candidate.
"The invitation to present at ASH (Free ASH Whitepaper) 2025 highlights international recognition of Grit Bio’s leadership in advancing in vivo CAR-T innovation," said Dr. Yarong Liu, Chairman and CEO of Grit Biotherapeutics. "Our GT801 platform represents a paradigm shift in cell therapy—transforming complex ex vivo manufacturing into a simple, repeatable, and scalable in vivo process. We are eager to share our latest clinical data and explore global partnerships that accelerate the translation of this breakthrough technology to patients worldwide."
(Press release, Grit Bio, NOV 4, 2025, View Source [SID1234659395])